Electrohypersensitivity as a Newly Identified and Characterized Neurologic Pathological Disorder: How to Diagnose, Treat, and Prevent It

Abstract

Overview

Since 2009, an extensive database of over 2000 self-reported cases has been established, analyzing individuals with Electrohypersensitivity (EHS) and/or Multiple Chemical Sensitivity (MCS). This comprehensive study reveals significant connections between EHS and MCS, highlighting how these conditions often coexist, influencing each other in terms of onset and development.

Findings

• The study indicates that 30% of EHS cases are associated with MCS, and in 37% of these cases, MCS precedes EHS.
• Both conditions share similar clinical symptoms and biological markers such as low-grade inflammation and autoimmune responses.
• A striking 80% of EHS patients display detectable oxidative stress biomarkers.
• Advanced imaging techniques have localized defects in cerebral artery hemodynamics and specific areas of the brain, suggesting the involvement of the limbic system and thalamus.

Conclusion

The data robustly support classifying EHS as a distinct neurologic pathological disorder. Recommendations have been made for the integration of EHS into the World Health Organization's international classification of diseases to enhance global awareness and drive further research and treatment methodologies. This action is deemed urgent to address the growing incidence of this contemporary health concern worldwide.